A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
← catalyst calendarNCT06568939 · readout ≤ 559 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
150estimated
Sites
80
Countries
Brazil, China, Israel +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-20 | actual | When the study began enrolling |
| Primary completion | Feb 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Small Cell Lung Cancer
Intervention
- Drug: Telisotuzumab Vedotin — also filed as ABBV-399
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants with Treatment-Emergent Adverse Events (AE)s (Any-grade and Grade >= 2)
measured Up to Approximately 3 Years
Percentage of Participants with Treatment-Emergent Interstitial Lung Disease (ILD)
measured Up to Approximately 3 Years
Percentage of Participants with Treatment-Emergent Peripheral Neuropathy
measured Up to Approximately 3 Years
Percentage of Participants with Treatment-Emergent Ocular Surface Disorders
measured Up to Approximately 3 Years
Percentage of Participants with Treatment-Emergent AEs Leading to Study Drug Discontinuation
measured Up to Approximately 3 Years
Percentage of Participants with Grade 5 Treatment-Emergent AEs
measured Up to Approximately 3 Years
Objective Response (OR) by Blinded Independent Central Review (BICR)
measured Up to Approximately 3 Years
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed